Methods for therapeutic vaccination
    2.
    发明公开
    Methods for therapeutic vaccination 审中-公开
    Verfahren zur therapeutischen Impfung

    公开(公告)号:EP1502602A2

    公开(公告)日:2005-02-02

    申请号:EP04076709.7

    申请日:1999-10-05

    申请人: Pharmexa A/S

    摘要: A method is disclosed for inducing cell-mediated immunity against cellular antigens. More specifically, the invention provides for a method for inducing cytotoxic T-lymphocyte immunity against weak antigens, notably self-proteins. The method entails that antigen presenting cells are induced to present at least one CTL epitope of the weak antigen and at the same time presenting at least one foreign T-helper lymphocyte epitope. In a preferred embodiment, the antigen is a cancer specific antigen, e.g. PSM, Her2, or FGF8b. The method can be exercised by using traditional polypeptide vaccination, but also by using live attenuated vaccines or nucleic acid vaccination. The invention furthermore provides immunogenic analogues of PSM, Her2 and FGF8b, as well as nucleic acid molecules encoding these analogues. Also vectors and transformed cells aer disclosed. The invention also provides for a method for identification of immunogenic analogues of weak or non-immunogenic antigens.

    摘要翻译: 公开了诱导针对细胞抗原的细胞介导的免疫的方法。 更具体地,本发明提供了针对弱抗原,特别是自身蛋白诱导细胞毒性T淋巴细胞免疫的方法。 该方法要求诱导抗原呈递细胞呈现弱抗原的至少一个CTL表位,同时呈现至少一种外源性T辅助淋巴细胞表位。 在优选的实施方案中,抗原是癌特异性抗原,例如, PSM,Her2或FGF8b。 该方法可以通过使用传统的多肽疫苗接种,也可以通过使用活减毒疫苗或核酸接种来进行。 本发明还提供PSM,Her2和FGF8b的免疫原性类似物以及编码这些类似物的核酸分子。 还公开了载体和转化细胞。 本发明还提供了用于鉴定弱或非免疫原性抗原的免疫原性类似物的方法。

    BETA-AMYLOID-ANALOGUE - T-CELL EPITOP VACCINE
    8.
    发明授权
    BETA-AMYLOID-ANALOGUE - T-CELL EPITOP VACCINE 有权
    BETA-AMYLOID-ANALOG - T-ZELL EPITOP IMPFSTOFF

    公开(公告)号:EP1420815B1

    公开(公告)日:2006-08-02

    申请号:EP02758181.8

    申请日:2002-08-20

    申请人: Pharmexa A/S

    摘要: Disclosed are novel methods for combatting diseases characterized by deposition of amyloid. The methods generally rely on immunization against amyloid precursor protien (APP) or beta amyloid (A²). Immunization is preferably effected by administration of analogues of autologous APP or A², said analogues being capable of inducing antibody production against the autologous amyloidogenic polypeptides. Especially preferred as an immunogen is autologous A² which has been modified by introduction of one single or a few foreign, immunodominant and promiscuous T-cell epitopes. Also disclosed are nucleic acid vaccination against APP or A² and vaccination using live vaccines as well as methods and means useful for the vaccination. Such methods and means include methods for the preparation of analogues and pharmaceutical formulations, as well as nucleic acid fragments, vectors, transformed cells, polypeptides and pharmaceutical formulations

    摘要翻译: 公开了以淀粉样沉积为特征的疾病的新型方法。 该方法通常依赖于针对淀粉样蛋白前体蛋白(APP)或β淀粉样蛋白(A 2)的免疫。 免疫优选通过施用自体APP或A 2的类似物来实现,所述类似物能够诱导针对自体淀粉样变性多肽的抗体产生。 特别优选的免疫原是自体A 2,其通过引入一个或多个外来的免疫显性和混杂的T细胞表位而被修饰。 还公开了针对APP或A 2的核酸疫苗接种和使用活疫苗的疫苗接种以及用于疫苗接种的方法和装置。 此类方法和手段包括制备类似物和药物制剂的方法,以及核酸片段,载体,转化细胞,多肽和药物制剂

    Novel method for down-regulation of amyloid
    9.
    发明公开
    Novel method for down-regulation of amyloid 审中-公开
    Neue Methode zur Herabregulierung von Amyloid

    公开(公告)号:EP1632242A2

    公开(公告)日:2006-03-08

    申请号:EP05021931.0

    申请日:2001-02-19

    申请人: Pharmexa A/S

    IPC分类号: A61K38/00 A61K38/16 A61K38/17

    摘要: Disclosed are novel methods for combatting diseases characterized by deposition of amyloid. The methods generally rely on immunization against amyloidogenic proteins (proteins contributing to formation of amyloid) such as beta amyloid (Aβ). Immunization is preferably effected by administration of analogues of autologous amyloidogenic polypeptides, said analogues being capable of inducing antibody production against the autologous amyloidogenic polypeptides. Especially preferred as an immunogen is autologous Aβ which has been modified by introduction of one single or a few foreign, immunodominant and promiscuous T-cell epitopes while substantially preserving the majority of Aβ's B-cell epitopes. Also disclosed are nucleic acid vaccination against amyloidogenic polypeptides and vaccination using live vaccines as well as methods and means useful for the vaccination. Such methods and means include methods for identification of useful immunogenic analogues of the amyloidogenic proteins, methods for the preparation of analogues and pharmaceutical formulations, as well as nucleic acid fragments, vectors, transformed cells, polypeptides and pharmaceutical formulations.

    摘要翻译: 公开了以淀粉样沉积为特征的疾病的新型方法。 该方法通常依赖于抗淀粉样变蛋白(有助于形成淀粉样蛋白的蛋白)如β淀粉样蛋白(A 2)的免疫。 免疫优选通过施用自体淀粉样蛋白多肽的类似物来实现,所述类似物能够针对自体淀粉样蛋白多肽诱导抗体产生。 作为免疫原特别优选的是自体A 2,其通过引入一个或少数外来的免疫优势和混杂的T细胞表位而被修饰,同时基本上保留了大部分A 2的B细胞表位。 还公开了针对淀粉样变性多肽的核酸疫苗接种和使用活疫苗的疫苗接种以及可用于疫苗接种的方法和装置。 这样的方法和手段包括用于鉴定淀粉样蛋白生成蛋白质的有用免疫原性类似物的方法,用于制备类似物和药物制剂的方法,以及核酸片段,载体,转化细胞,多肽和药物制剂。

    IMPROVED PROTEIN EXPRESSION
    10.
    发明公开
    IMPROVED PROTEIN EXPRESSION 审中-公开
    改进的蛋白质表达

    公开(公告)号:EP1913143A1

    公开(公告)日:2008-04-23

    申请号:EP05762730.9

    申请日:2005-07-29

    申请人: Pharmexa A/S

    发明人: KJÆRULFF, Søren

    IPC分类号: C12N15/62 C12N15/81

    CPC分类号: C12N15/815 C07K2319/036

    摘要: Disclosed is chimeric polynucleotides adopted for providing high-yield expression and secretion of recombinant polypeptides. The chimeric polynucleotide of the invention includes a functional secretion signal peptide derived from S. pombe carboxypeptidase Y (CPY). The invention also discloses methods for use of this cpy leader sequence.